brentuximab vedotin

We ship brentuximab manufactured in Austria by cold chain shipping from our pharmacy in India.

Information About brentuximab

brentuximab treats Hodgkin lymphoma, systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, and CD30-expressing mycosis fungoides.

It targets tumor cells expressing the CD30 antigen, which is characteristic of Hodgkin lymphoma and ALCL.

Product Highlights

• brentuximab vedotin consists of 3 main components:

                       The chimeric IgG1 antibody cAC10, targeting human CD30.

                       The microtubule disrupting agent MMAE.

                       A protease-cleavable linker that attaches MMAE to cAC10 covalently.

• brentuximab vedotin is use for the treatment of in adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) who have done at least 1 prior systemic therapy.

Key Ingredients

• Trehalose dihydrate
• Sodium citrate dihydrate
• Citric acid monohydrate
• Polysorbate 80
• Water for injection

Key Benefits

• The benefits of brentuximab vedotin include targeted therapy against CD30-expressing cancers like Hodgkin lymphoma and systemic anaplastic large cell lymphoma, potentially leading to more effective treatment outcomes with reduced impact on healthy cells.

Direction For Use

• Sample calculations for patients receiving the recommended dose of 1.8 mg/kg of brentuximab for weights ranging from 60 kg to 120 kg.

Patient weight (kg)	Total dose = patient weight multiplied by recommended dose [1.8 m g/kga ])	Total volume to be diluted = total dose divided by reconstituted vial concentration [5 mg/mL])	Number of vials needed = total volume to be diluted divided by total volume per vial [10 mL/vial])
60 kg	108 mg	21.6 mL	2.16 vials
80 kg	144 mg	28.8 mL	2.88 vials
100 kg	180 mg	36 mL	3.6 vials
120 kg c	18 mg d	36 mL	3.6 vials

 

• Sample calculations for patients receiving the recommended dose of 1.2 mg/kg of brentuximab for weights ranging from 60 kg to 120 kg when a reduced dose is required.

Patient weight (kg)	Total dose = patient weight multiplied by recommended dose [1.2 mg/kg])	Total volume to be diluted = total dose divided by reconstituted vial concentration [5 mg/mL])	Total volume to be diluted = total dose divided by reconstituted vial concentration [5 mg/mL])
60 kg	72 mg	14.4 mL	1.44 vials
80 kg	96 mg	19.2 mL	1.92 vials
100 kg	120 mg	24 mL	2.4 vials
120 kg b	120 mg	24 mL	2.4 vials

Safety Concern

• Read the label carefully before use.
• Do not exceed the recommended dose.
• brentuximab vedotin may include potential side effects such as infusion reactions, peripheral neuropathy, and risk of infections.

How to Take

• For brentuximab vedotin, follow the directions provided by your healthcare provider regarding administration and dosage.

Avoid Taking brentuximab If:

• You have an allergy to brentuximab
• The packaging is torn or has signs of tampering.
• The medicine has expired as it may not work if taken after the expiry date.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.